论文部分内容阅读
丙二胺亚胺(ICRF_(159))系双-二酮哌嗪衍生物,1969年试用于临床。既往仅对少数急性白血病患者作了有限研究。作者单纯用ICRF_(159)治疗28例急性非淋巴细胞白血病(ANLL),16例急性淋巴细胞白血病(ALL)和2例急性未分化白血病(AUL)的病人。此类病例均系对常规治疗耐药的难治性晚期急性白血病。该46例(除3例儿童外均为成年患者)共接受ICRF_(159)183个疗程(平均4,中数2,范围1～35个疗程),剂量为150～500毫克/米~2/天,每8小时口服一次,3～5天为一疗程,间隔1～3周。大多数病例开始
Proparadiamine (ICRF_(159)) is a bis-diketopiperazine derivative that was clinically tested in 1969. Only a limited number of patients with acute leukemia have been studied in the past. The authors used ICRF_(159) alone to treat 28 patients with acute non-lymphocytic leukemia (ANLL), 16 patients with acute lymphoblastic leukemia (ALL), and 2 patients with acute undifferentiated leukemia (AUL). These cases are refractory to routine treatment of refractory advanced acute leukemia. The 46 patients (all adult patients except 3 children) received ICRF_(159) 183 courses (average 4, median 2, range 1 to 35 courses) at a dose of 150 to 500 mg/m 2/ Days, oral once every 8 hours, 3 to 5 days for a course of treatment, interval 1 to 3 weeks. Most cases begin